Operative treatment of prolactinomas: Indications and results in a current consecutive series of 212 patients

European Journal of Endocrinology

Volumn 158, Issue 1, 2008, Pages 11-18

  Kreutzer, J ^a   Buslei, R ^a   Wallaschofski, H ^a   Hofmann, B ^a   Nimsky, C ^a   Fahlbusch, R ^a   Buchfelder, M ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; DECISION MAKING; DISEASE CLASSIFICATION; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROLACTINOMA; RECURRENCE RISK; REMISSION; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TRANSSPHENOIDAL SURGERY; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; CHILD; DOPAMINE AGONISTS; FEMALE; HUMANS; HYPOGONADISM; HYPOPITUITARISM; HYPOTHYROIDISM; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PITUITARY-ADRENAL SYSTEM; POSTOPERATIVE COMPLICATIONS; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 38949200317     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0248     Document Type: Article

References (39)

1. Ciccarelli A, Daly AF & Beckers A. The epidemiology of prolactinomas. Pituitary 2005 8 3-6.
2. Vance ML & Thorner MO Prolactin: hyperprolactinemic syndromes and management. In Ed. LJ De Groot, Textbook of Endocrinology, edn 2, WB Saunders Company, Philadelphia, London, Toronto, Mexico City, Rio de Janeiro, Sydney, Tokyo, Hong Kong, 1989, pp. 408-418.
3. Thorner MO, McNeilly AS, Hagan C & Besser GM. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. BMJ 1974 2 419-422.
4. Werder K, Fahlbusch R, Landgraf R, Pickardt CR, Rjosk HK & Scriba PC. Treatment of patients with prolactinomas. Journal of Endocrinological Investigation 1978 1 47-58.
5. Bevan JS, Webster J, Burke CW & Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocrine Reviews 1992 13 220-240.
6. Molitch ME, Thorner MO & Wilson C. Management of prolactinomas. Journal of Clinical Endocrinology and Metabolism 1997 82 996-1000.
7. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Safety 1996 14 228-238.
8. Webster J, Piscitelli G, Polli A, Ferrari Cl, Ismail I & Scanlon MF. For the Cabergoline Comparative Study Group. New England Journal of Medicine, 1994 904-909.
9. Boyd A. Bromocriptine and psychosis: a literature review. Psychiatric Quarterly 1995 66 87-95.
10. Colao A, Vitale G, Cappabianca P, Brigand F, Ciccarelli A, De Rosa M, Zarrilli S & Lombardi G. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. Journal of Clinical Endocrinology and Metabolism 2004 89 1704-1711.
11. Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary 2002 5 55-65.
12. Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, L'Hermite M, Ciccarelli E, Crogsignani PG, Dedecco L, Fandini R, Faglia G, Flamigni C, Tamburrano G, Ismail I & Scanlon MF. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clinical Endocrinology 1993 39 323-329.
13. Colao A, Merola B, Sarnacchiaro E Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D & Lombardi G. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Hormone Research 1995 5 222-228.
14. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S & Lombardi G. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. Journal of Clinical Endocrinology and Metabolism 2004 4 1704-1711.
15. Verhelst 1, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C & Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Journal of Clinical Endocrinology and Metabolism, 1999 2518-2522.
16. Colao A, De Rosa M, Sarnacchiaro F, Di Sarno A, Landi ML, lervolino E, Zarrilli S, Merola B & Lombardi G. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. European Journal Endocrinology 1996 135 548-552.
17. Colao A, di Sarno A, Pivonello R, di Somma C & Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opinion on Investigational Drugs 2002 11 787-800.
18. Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D & Lombardi G. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Hormone Research 1995 44 222-228.
19. Serri O, Beauregard H, Lesage J, Pedneault L, Comtois R, Jilwan N, Somma M, Vachon L & Brownell J. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas. Journal of Clinical Endocrinology and Metabolism 1990 71 682-687.
20. van der Lely AJ, Brownell J & Lamberts SW The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. Journal of Clinical Endocrinology and Metabolism 1991 72 1136-1141.
21. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R & Lombardi G. Withdrawal of long-term cabergoline therapy for tumoural and nontumoural hyperprolactinemia. New England Journal of Medicine 2003 349 2023-2033.
22. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF & Davies JS. Long-term remission following withdrawal of doparnine agonist therapy in subjects with microprolactinomas. Clinical Endocrinology 2005 63 26-31.
23. Nomikos P, Buchfelder M & Fahlbusch R. Current management of prolactinomas. Journal of Neuro-Oncology 2001 54 139-150.
24. Abe T & Ludecke DK. Transnasal surgery for prolactin-secreting pituitary adenomas in childhood and adolescence. Surgical Neurology 2002 57 369-378 (discussion 378-379).
25. Couldwell WT, Rovit RL & Weiss MH. Role of surgery in the treatment of microprolactinomas. Neurosurgery Clinics of North America 2003 14 89-92 (vii).
26. Feigenbaum SL, Downey DE, Wilson CB & Jaffe RB. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. Journal of Clinical Endocrinology and Metabolism 1996 81 1711-1719.
27. Massoud F, Serri O, Hardy J, Somma M & Beauregard H. Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surgical Neurology 1996 45 341-346.
28. Mortini P, Losa M, Barzaghi R, Boari N & Giovanelli M. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 2005 56 1222-1233 (discussion 1233).
29. Post KD, Biller BJ, Adelman LS, Molitch ME, Wolpert SM & Reichlin S. Selective transsphenoidal adenomectomy in women with galactorrhea-amenorrhea. Journal of the American Medical Association 1979 242 158-162.
30. Randall RV, Laws ER, Jr, Abboud CF, Ebersold MJ, Kao PC & Scheithauer BW Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clinic Proceedings 1983 58 108-121.
31. Turner HE, Adams CB & Wass JA. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists? European Journal of Endocrinology 1999 140 43-47.
32. Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB & Wilson CB. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 1999 44 254-261 (discussion 261-263).
33. Wolfsberger S, Czech T, Vierhapper H, Benavente R & Knosp E. Microprolactinomas in males treated by transsphenoidal surgery. Acta Neurochirurgica 2003 145 935-940 (discussion 940-941).
34. Losa M, Mortini P, Barzaghi R, Gioia L & Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. Journal of Clinical Endocrinology and Metabolism 2002 87 3180-3186.
35. Casanucva PF, Molitch ME, Schlechte JA, Abs R, Bonert V Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws ER, Marek J, Scanlon W, Sobrinho LG, Wass JA & Giustina A. Guidlines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology 2006 65 265-273.
36. DeLellis RA, Lloyd RV, Heitz PU, Eng C. (Eds) Pathology and Genetics of Tumours of Endocrine Organs. Oxford University Press, 2004.
37. Thomson JA, Davies DL, McLaren E & Teasdale GM. Ten year follow-up of microprolactinoma treated by transsphenoidal surgery. BMJ 1994 309 1409-1410.
38. Serri O, Rasio E, Beauregard H, Hardy J & Somma M. Recurrence of hyperprolactinemia after selective adenomectomy in women with prolactinoma. New England Journal of Medicine 1983 309 280-283.
39. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S & Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine 2007 356 39-46.